CGAS and colitis: Prop-2-yn-1-one had potential to be further developed for inflammatory disease therapies.Pretreatment of a novel cGAS inhibitor inhibited the activation of STING pathway after Interferon Stimulatory DNA treatment in macrophages via covalently bind to Cys419 of cGAS. Intraperitoneally injected cGAS inhibitor ameliorated DSS-induced colitis in mice.